In summary, we generated a de novo KI mouse model to demonstrate LINK‐A to be an effective RNA‐based therapeutic drug target to treat HFD‐induced obesity, evidenced by the nucleic acid drug ASO preventing the developing HFD‐induced obesity in LINK‐A KI mice. This evidence concerns the gene LINC01139 and obesity disorder.